A recent market study published by Future Market Insights (FMI) on the GLP-1 Receptor Agonist Market offers global industry analysis for 2015-2019 & opportunity assessment for 2020-2030. The report consists of a comprehensive assessment of the most important market dynamics. On conducting thorough research on the historical as well as current growth parameters of the market, growth prospects of the market are obtained with utmost precision.
The report features unique and salient factors that may make a huge impact on the development of the GLP-1 Receptor Agonist Market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in the market in the years to come. The report provides detailed information about the current and future growth prospects of the market in the most comprehensive way for better understanding of readers.
GLP-1 receptor agonist, also known as incretin mimetics, represents a class of medications used in the treatment of type 2 diabetes mellitus and obesity in adults. Drugs in the GLP-1 Receptor agonist include exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, and semaglutide. Extensive R&D is a key driver of the GLP-1 receptor agonist market. Several pharmaceutical and biotecnology development companies are engaged in R&D for the development of new formulations and molecules.
To know more about this market, request a sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-12346
Key Takeaways from the GLP-1 Receptor Agonist Market
- Trulicity held the largest share in terms of revenue generation in 2019
- Ozempic is expected to witness the highest growth rate between 2020 and 2030 owing to advantages like weight loss, reduction of cardiovascular risk, and controlled levels of haemoglobin
- Asia Pacific is expected to be growing at the fastest pace due to onslaught of diabetes supporting intake of GLP-1 receptor agonists
Key Segment
Drug Class
- Exenatide
- Liraglutide
- Dulaglutide
- Lixisenatide
- Others
Route of Administration
- Parenteral
- Oral
Distribution Channel
- Hospitals
- Clinics
- Ambulatory Surgical Centres
Region
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa
Key Players Operating in Global GLP-1 Receptor Agonist Market
However, some time back, Teva did confirm generic Victoza. It also stated that it had filed ANDA (abbreviated new drug application) with the US FDA, thereby asking for approval for marketing Novo Nordisk’s Victoza (Iiraglutide) injection in the US.
The global GLP-1 receptor agonist market is fragmented, with presence of a large number of small-scale and large-scale companies. Leading companies operating in the global GLP-1 receptor agonist market are: Eli Lilly and Company, Novo Nordisk, AstraZeneca, Intarcia Therapeutics, Sanofi, Jiangsu Hengrui Medicine Co., Hanmi Pharmaceutical, PegBio, Pfizer, Amgen, Innovent Biologics
Get Access to Research Methodology Prepared by Experts>>> https://www.futuremarketinsights.com/ask-question/rep-gb-12346
Want more insights?
GLP-1 Receptor Agonist market, a new study from Future Market Insights, states the indications of GLP-1 Receptor Agonist market from 2015 to 2019 and presents demand projections from 2020 from 2030 on the basis of drug class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, and Others), route of administration (parenteral, oral), distribution channel (Hospitals, Clinics, Ambulatory Surgical Centres) across seven prominent regions. In other words, a snapshot of every sub-section; that too, region-wise is presented in the report by FMI.